Global Information
회사소개 | 문의

복막암 : 파이프라인 리뷰

Peritoneal Cancer - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 229745
페이지 정보 영문 1220 Pages
가격
US $ 2,000 ₩ 2,287,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,575,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,863,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


복막암 : 파이프라인 리뷰 Peritoneal Cancer - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 1220 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

복막암은 복막에 발생하는 희귀암입니다. 복막은 복벽의 안쪽을 덮는 얇은 막으로, 자궁에서 방광, 직장까지 넓은 범위에 이릅니다. 복막암은 복부 팽만, 복수를 동반한 광범위한 비특이적 복통이 생기는 것이 일반적입니다. 호흡 곤란, 직장 출혈, 식욕 부진, 빈뇨, 변비, 구역질, 설사,(가벼운 식사 후에도 들게 되는) 포만감 등의 증상이 나타납니다. 치료법으로 화학요법, 수술, 생물학적 요법, 방사선 요법 등이 있습니다.

복막암(Peritoneal Cancer) 치료제의 개발 상황에 대해 조사 분석하고, 파이프라인 제품 개요, 임상 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

복막암 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

복막암 : 기업에서 개발중인 치료제

복막암 : 대학/기관에서 연구중인 치료제

복막암 : 파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

복막암 : 기업에서 개발중인 제품

복막암 : 대학/기관에서 연구중인 제품

복막암 치료제 개발에 참여하고 있는 기업

  • AbbVie Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech, Inc.
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Atara Biotherapeutics, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Caladrius Biosciences, Inc.
  • Celldex Therapeutics, Inc.
  • Celsion Corporation
  • CerRx, Inc.
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Corcept Therapeutics Incorporated
  • Critical Outcome Technologies Inc.
  • CritiTech, Inc.
  • CTI BioPharma Corp.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Ganymed Pharmaceuticals AG
  • Genelux Corporation
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • Glycotope GmbH
  • Gradalis Inc.
  • Hemispherx Biopharma, Inc.
  • ImmunoGen, Inc.
  • Immunovaccine, Inc.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Kyowa Hakko Kirin Co.
  • Lee's Pharmaceutical Holdings Limited
  • Mabion SA
  • MabVax Therapeutics Holdings, Inc.
  • MedImmune, LLC
  • Medivation, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OBI Pharma, Inc.
  • Oncobiologics, Inc.
  • Oncolix, Inc.
  • Oncolytics Biotech Inc.
  • OncoMed Pharmaceuticals, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Oxford BioMedica Plc
  • OXiGENE, Inc.
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • PsiOxus Therapeutics Limited
  • Quest PharmaTech Inc.
  • Sanofi Pasteur SA
  • Shenzen SiBiono GeneTech Co., Ltd.
  • Sotio a.s.
  • Synta Pharmaceuticals Corp.
  • TapImmune Inc.
  • Tesaro, Inc.
  • TetraLogic Pharmaceuticals
  • Tyrogenex, Inc.
  • Vascular Biogenics Ltd.
  • VentiRx Pharmaceuticals, Inc.

복막암 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

복막암 : 최근의 파이프라인 동향

복막암 : 휴지 상태인 프로젝트

복막암 : 개발이 중지된 제품

복막암 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.10.07

List of Tables

  • Number of Products under Development for Peritoneal Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Peritoneal Cancer - Pipeline by 3-V Biosciences Inc, H2 2018
  • Peritoneal Cancer - Pipeline by AbbVie Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Peritoneal Cancer - Pipeline by AiVita Biomedical Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Aldeyra Therapeutics Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Altor BioScience Corp, H2 2018
  • Peritoneal Cancer - Pipeline by ALX Oncology Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Amgen Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2018
  • Peritoneal Cancer - Pipeline by Astellas Pharma Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
  • Peritoneal Cancer - Pipeline by AstraZeneca Plc, H2 2018
  • Peritoneal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Bayer AG, H2 2018
  • Peritoneal Cancer - Pipeline by BeiGene Ltd, H2 2018
  • Peritoneal Cancer - Pipeline by Biocon Ltd, H2 2018
  • Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Peritoneal Cancer - Pipeline by Boston Biomedical Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Peritoneal Cancer - Pipeline by Celgene Corp, H2 2018
  • Peritoneal Cancer - Pipeline by Celsion Corp, H2 2018
  • Peritoneal Cancer - Pipeline by CerRx Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2018
  • Peritoneal Cancer - Pipeline by Clovis Oncology Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Corcept Therapeutics Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Peritoneal Cancer - Pipeline by Eisai Co Ltd, H2 2018
  • Peritoneal Cancer - Pipeline by Eli Lilly and Co, H2 2018
  • Peritoneal Cancer - Pipeline by EpiThany Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Epizyme Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Exelixis Inc, H2 2018
  • Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Peritoneal Cancer - Pipeline by Fate Therapeutics Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Forty Seven Inc, H2 2018
  • Peritoneal Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2018
  • Peritoneal Cancer - Pipeline by Genelux Corp, H2 2018
  • Peritoneal Cancer - Pipeline by Genmab A/S, H2 2018

List of Figures

  • Number of Products under Development for Peritoneal Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H2 2018, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 14, 78, 52, 17, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 1 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Peritoneal Cancer - Overview
  • Peritoneal Cancer - Therapeutics Development
  • Peritoneal Cancer - Therapeutics Assessment
  • Peritoneal Cancer - Companies Involved in Therapeutics Development
  • Peritoneal Cancer - Drug Profiles
  • Peritoneal Cancer - Dormant Projects
  • Peritoneal Cancer - Discontinued Products
  • Peritoneal Cancer - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research